Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | ALPG | P10696 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14069484 | 0.83 | CYP19A1 (0.50) | CYP19A1ALPGALPITDP1PLAA | |
| SCHEMBL8537952 | 0.83 | CYP19A1 (0.50) | CYP19A1ALPGALPITDP1PLAA | |
| SCHEMBL10247467 | 0.79 | CYP19A1 (0.72) | CYP19A1ALPGALPITDP1PLAA | |
| Hydrochloric Acid SCHEMBL408248 | 0.78 | CYP19A1 (0.70) | CYP19A1ALPGALPITDP1PLAA | |
| SCHEMBL11022381 | 0.78 | CYP19A1 (0.54) | CYP19A1ALPGALPITDP1PLAA | |
| SCHEMBL15286081 | 0.77 | MAPK1 (0.41) | CYP19A1ALDH1A1KDM4ECYP11B1CYP11B2 | |
| SCHEMBL15286082 | 0.77 | MAPK1 (0.41) | CYP19A1ALDH1A1KDM4ECYP11B1CYP11B2 | |
| SCHEMBL4890004 | 0.76 | ALPL (0.51) | ALPGPLAAALDH1A1KDM4E | |
| SCHEMBL9996076 | 0.75 | CYP19A1 (0.67) | CYP19A1ALPGALPITDP1PLAA | |
| SCHEMBL30998281 | 0.74 | KDM4E (0.46) | CYP19A1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013144224-A1 | ACETYLENIC MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144224-A1 | ACETYLENIC MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-10-03 | — | — | WO | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| EP-2134721-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | Micurx Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| EP-1753754-A1 | 3- '4- {6-SUBSTITUTED ALKANOYL) PYRIDIN-3-YL} -3-PHENYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005116022-A1 | 3- `4- {6-SUBSTITUTED ALKANOYL) PYRIDIN-3-YL} -3-PHENYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021012-A1 | 3-[4-{6-Substituted Alkanoyl Pyridin-3-Yl}-3-Phenyl]-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones As Antibacterial Agents | MRPL21, ARG1, OXA1L | CYP19A1 3601/4885ALPG 3966/4885ALPI 228/4885 |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | CYP19A1 2036/4885ALPG 1148/4885ALPI 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.